Under the new priority voucher program (CNPV), the FDA has approved a new oral GLP-1 drug, Foundayo, offering an alternative ...
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today highlighted a legislative proposal contained in the FDA's FY 2027 ...
FDA approved the Eli Lilly’s daily weight‑loss pill, a fast‑tracked GLP‑1 drug offering a new option for obesity treatment.
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application ...
First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage diseaseFirst FDA-approved ...
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of ...
The FDA has extended the deadline to review Orca-T for the treatment of myelodsyplastic syndromes and acute leukemias with a ...
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today highlighted a legislative proposal contained in the FDA's FY 2027 ...
"It is the completion of the FDA's promised review of the mifepristone REMS, not 'government by lawsuit' that this Court ...
Orforglipron is the second daily weight-loss pill to hit the market. The first was the Wegovy pill, from Novo Nordisk, which ...
The brief reign of Novo Nordisk’s Wegovy pill as the lone oral GLP-1 approved for obesity has ended as Eli Lilly’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results